Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

San Diego based Abide Therapeutics is collaborating with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, a validated but under-explored class of drug targets.

Under the three-­year agreement, Abide and Oxford will explore the role of monoacylglycerol lipase (MGLL) inhibitors in altering endocannabinoid tone in the human brain.

The collaboration will combine the unique experience and capabilities of the Oxford Centre for Functional MRI of the Brain (FMRIB), led by Irene Tracey, with Abide’s unique chemoproteomics platform. The goals of the collaboration are to explore MGLL in a number of clinical indications including pain and inflammatory conditions. 

This collaboration is part of our commitment to translate research discoveries into the clinic to develop new medicines to improve survival and quality of life for patients around the world.
- Sir John Bell, Regius Professor of Medicine, University of Oxford

“This collaborative agreement is a true delight as it extends the founding vision of Abide which is to partner with enlightened academic investigators that have unique insights into how best to test novel therapies at the earliest stages of clinical development,” said Alan Ezekowitz, President and CEO of Abide.

Under the agreement, Abide will provide support for at least three Phase 1B studies as well as for directed new target discovery efforts. The collaboration has been supported through the NIHR Oxford Biomedical Research Centre

Similar stories

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Visit from the Sir Jules Thorn Charitable Trust

Earlier this month, we were delighted to welcome the Director of the Sir Jules Thorn Charitable Trust, Richard Benson, and its Chair of Trustees, Liz Charal.